Chad R Schultz1, Matthew A Swanson2, Thomas C Dowling3, André S Bachmann4. 1. Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, 400 Monroe Ave, NW, Grand Rapids, MI, 49503, USA. 2. Shimadzu Core Laboratory for Academic and Research Excellence, Ferris State University, Big Rapids, MI, USA. 3. Department of Pharmaceutical Sciences, College of Pharmacy, Ferris State University, Big Rapids, MI, USA. 4. Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, 400 Monroe Ave, NW, Grand Rapids, MI, 49503, USA. bachma26@msu.edu.
Abstract
BACKGROUND: Neuroblastoma (NB) is the most common extracranial solid tumor in children. Interference with the polyamine biosynthesis pathway by inhibition of MYCN-activated ornithine decarboxylase (ODC) is a validated approach. The ODC inhibitor α-difluoromethylornithine (DFMO, or Eflornithine) has been FDA-approved for the treatment of trypanosomiasis and hirsutism and has advanced to clinical cancer trials including NB as well as cancer-unrelated human diseases. One key challenge of DFMO is its rapid renal clearance and the need for high and frequent drug dosing during treatment. METHODS: We performed in vivo pharmacokinetic (PK), antitumorigenic, and molecular studies with DFMO/probenecid using NB patient-derived xenografts (PDX) in mice. We used LC-MS/MS, HPLC, and immunoblotting to analyze blood, brain tissue, and PDX tumor tissue samples collected from mice. RESULTS: The organic anion transport 1/3 (OAT 1/3) inhibitor probenecid reduces the renal clearance of DFMO and significantly increases the antitumor activity of DFMO in PDX of NB (P < 0.02). Excised tumors revealed that DFMO/probenecid treatment decreases polyamines putrescine and spermidine, reduces MYCN protein levels and dephosphorylates retinoblastoma (Rb) protein (p-RbSer795), suggesting DFMO/probenecid-induced cell cycle arrest. CONCLUSION: Addition of probenecid as an adjuvant to DFMO therapy may be suitable to decrease overall dose and improve drug efficacy in vivo.
BACKGROUND:Neuroblastoma (NB) is the most common extracranial solid tumor in children. Interference with the polyamine biosynthesis pathway by inhibition of MYCN-activated ornithine decarboxylase (ODC) is a validated approach. The ODC inhibitor α-difluoromethylornithine (DFMO, or Eflornithine) has been FDA-approved for the treatment of trypanosomiasis and hirsutism and has advanced to clinical cancer trials including NB as well as cancer-unrelated human diseases. One key challenge of DFMO is its rapid renal clearance and the need for high and frequent drug dosing during treatment. METHODS: We performed in vivo pharmacokinetic (PK), antitumorigenic, and molecular studies with DFMO/probenecid using NB patient-derived xenografts (PDX) in mice. We used LC-MS/MS, HPLC, and immunoblotting to analyze blood, brain tissue, and PDX tumor tissue samples collected from mice. RESULTS: The organic anion transport 1/3 (OAT 1/3) inhibitor probenecid reduces the renal clearance of DFMO and significantly increases the antitumor activity of DFMO in PDX of NB (P < 0.02). Excised tumors revealed that DFMO/probenecid treatment decreases polyamines putrescine and spermidine, reduces MYCN protein levels and dephosphorylates retinoblastoma (Rb) protein (p-RbSer795), suggesting DFMO/probenecid-induced cell cycle arrest. CONCLUSION: Addition of probenecid as an adjuvant to DFMO therapy may be suitable to decrease overall dose and improve drug efficacy in vivo.
Authors: Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel Journal: N Engl J Med Date: 2010-09-30 Impact factor: 91.245
Authors: Katherine K Matthay; John M Maris; Gudrun Schleiermacher; Akira Nakagawara; Crystal L Mackall; Lisa Diller; William A Weiss Journal: Nat Rev Dis Primers Date: 2016-11-10 Impact factor: 52.329
Authors: Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Arlene Naranjo; Mitchell B Diccianni; Jacek Gan; Jacquelyn A Hank; Ayse Batova; Wendy B London; Sheena C Tenney; Malcolm Smith; Barry L Shulkin; Marguerite Parisi; Katherine K Matthay; Susan L Cohn; John M Maris; Rochelle Bagatell; Julie R Park; Paul M Sondel Journal: Clin Cancer Res Date: 2021-01-27 Impact factor: 13.801
Authors: Trevor J Pugh; Olena Morozova; Edward F Attiyeh; Shahab Asgharzadeh; Jun S Wei; Daniel Auclair; Scott L Carter; Kristian Cibulskis; Megan Hanna; Adam Kiezun; Jaegil Kim; Michael S Lawrence; Lee Lichenstein; Aaron McKenna; Chandra Sekhar Pedamallu; Alex H Ramos; Erica Shefler; Andrey Sivachenko; Carrie Sougnez; Chip Stewart; Adrian Ally; Inanc Birol; Readman Chiu; Richard D Corbett; Martin Hirst; Shaun D Jackman; Baljit Kamoh; Alireza Hadj Khodabakshi; Martin Krzywinski; Allan Lo; Richard A Moore; Karen L Mungall; Jenny Qian; Angela Tam; Nina Thiessen; Yongjun Zhao; Kristina A Cole; Maura Diamond; Sharon J Diskin; Yael P Mosse; Andrew C Wood; Lingyun Ji; Richard Sposto; Thomas Badgett; Wendy B London; Yvonne Moyer; Julie M Gastier-Foster; Malcolm A Smith; Jaime M Guidry Auvil; Daniela S Gerhard; Michael D Hogarty; Steven J M Jones; Eric S Lander; Stacey B Gabriel; Gad Getz; Robert C Seeger; Javed Khan; Marco A Marra; Matthew Meyerson; John M Maris Journal: Nat Genet Date: 2013-01-20 Impact factor: 38.330
Authors: Lucas Moreno; Giuseppe Barone; Steven G DuBois; Jan Molenaar; Matthias Fischer; Johannes Schulte; Angelika Eggert; Gudrun Schleiermacher; Frank Speleman; Louis Chesler; Birgit Geoerger; Michael D Hogarty; Meredith S Irwin; Nick Bird; Guy B Blanchard; Sean Buckland; Hubert Caron; Susan Davis; Bram De Wilde; Hedwig E Deubzer; Emmy Dolman; Martin Eilers; Rani E George; Sally George; Štěrba Jaroslav; John M Maris; Lynley Marshall; Melinda Merchant; Peter Mortimer; Cormac Owens; Anna Philpott; Evon Poon; Jerry W Shay; Roberto Tonelli; Dominique Valteau-Couanet; Gilles Vassal; Julie R Park; Andrew D J Pearson Journal: Eur J Cancer Date: 2020-07-09 Impact factor: 10.002